Basecamp Research announced a $140m Series C on 23 September, raised to train a new generation of its EDEN models and push a pipeline of AI-designed therapeutics towards clinical development. The oversubscribed round values the London-based company at $800m.
S32 led. Nvidia, Anthropic’s Anthology Fund, Catalio Capital Management, the NATO Innovation Fund, the Rockefeller Foundation and Singular took part, as reported by GEN.
What the company is actually building
Basecamp’s stated ambition is to design medicines that reprogram the body to repair itself, combining frontier models trained on proprietary biological data with technology for writing DNA sequences into cells. Its first focus is in vivo cell therapy — engineering cells inside the patient rather than extracting, modifying and returning them.
The proprietary data is the part that distinguishes this from a modelling exercise. Basecamp has built its position on biological data it collects itself rather than on public sequence databases, which is the constraint every protein model eventually runs into: the public corpus is finite, heavily biased towards organisms that are easy to culture, and shared by every competitor.
The investor list is the second story
Nvidia sells the compute. Anthropic’s Anthology Fund is a model lab investing in an application of models to biology, one week after Anthropic published its own claim that Claude had rewritten and accelerated more than 30 open biomolecular models. The NATO Innovation Fund’s presence puts a defence-adjacent investor into a company working on rewriting cellular behaviour, which is a combination worth noting even when the stated pipeline is therapeutic.
What the round does not tell you
An $800m valuation on a company with no clinical data is a bet on the platform, not on a drug. Basecamp has not published clinical results, and the announcement describes programmes advancing towards clinical development rather than in it. The gap between a designed molecule and a dosed patient is where most of this category has historically stalled.
What to watch
Whether Basecamp names a lead programme and an indication, and whether any of the EDEN models or their evaluations are published in a form outside researchers can check. A platform company that keeps both its data and its model private is asking to be taken on trust.
